CA-PATIENT-SAFETY-MOVE
31.8.2021 14:02:09 CEST | Business Wire | Press release
The second annual #UniteForSafeCare event is scheduled for Friday, September 17th in conjunction with World Patient Safety Day. The event is hosted by the Patient Safety Movement Foundation (PSMF) and co-convened with The Leapfrog Group to bring global awareness to the lack of safety in healthcare and the fact that more than three million people die each year as the result of unsafe care. The event will explore how the public and other stakeholders can call for high reliability in healthcare, as well as the World Health Organization’s 2021 theme of “safe maternal and newborn care.”
As part of this year’s event, leadership from the Patient Safety Movement Foundation will coordinate demonstrations on both the east and west coasts in honor of World Patient Safety Day. Patient Safety Movement Foundation CEO Dr. David B. Mayer will continue his walk which began in February 2020 to raise awareness of patient and healthcare worker safety. Since starting, he has covered over 3,400 miles and been joined by families impacted by patient harm in over 30 states. This year’s walk will begin on September 11th on the 20th anniversary of the terrorist attacks to honor the lives lost and impacted, and will start in Gettysburg, Penn. Gettysburg was chosen as the starting point due to its strong visual representation of lives lost during the American Civil War drawing parallel to the lives lost each day due to unsafe care. The walk will finish in front of the White House in a call for action before continuing on to Capitol Hill.
“Over 8,220 people die every day in hospitals worldwide from unsafe care – that’s six people every minute – and the pandemic is making the delivery of safe care even harder,” stated Mayer. “This annual event allows us to bring the community and stakeholders together to raise awareness of this issue and advocate for change to make zero preventable deaths a reality.”
Here are the ways you can get involved this year:
- Attend the free virtual event: The virtual event will occur from 11 a.m. to 3:15 p.m. PDT on Friday, September 17th. At the event, attendees will have the chance to hear from Patient Safety Movement Foundation leadership, as well as over 20 speakers including Tedros Adhanom Ghebreyesus, PhD, MSc, director-general of the World Health Organization. Dariush Eghbali, an Iranian artist and humanitarian, will be performing and attendees will have the opportunity to network and access exhibitor booths. In addition, there will be a panel with the showrunner and cast of Peacock’s TV series “Dr. Death” followed by a segment to memorialize the patients we’ve lost due to preventable harm. Attendees will have the opportunity to bid on items up for auction – including a private screening and Q&A session with the filmmaker of HBO’s “Bleed Out,” as well as a conversation with Patrick Macmanus, the showrunner of “Dr. Death.” All proceeds of the auction support awareness and education initiatives. To see the full schedule and RSVP, visit: https://patient.sm/B15-UFSC .
- Host your own walk: Download the Charity Miles app and walk on your own or invite your coworkers and community to dedicate a walk, run, bike or any movement to show your support for the cause.
- Make a donation : Donations help fund awareness and education campaigns throughout the year. Individuals can make donations in honor of loved ones who have been affected by preventable medical harm. PSMF will plant an orange flag in Orange County or Washington D.C. for any donation of $10 or more. To help PSMF reach its goal of $250,000, visit: https://patient.sm/PR-UFSC-Donate .
- Share on social: Spread the word and help advocate for safer care by increasing awareness on social media. Use the hashtag #uniteforsafecare or translate it into any language to keep the conversation going globally.
- Send in your art: New this year, a virtual patient, family and survivor art gallery is available for individuals to share personal expressions of the emotions they felt as they navigated experiences with medical errors – whether it ended in tragedy or in joy. The art will be displayed along with a place to share the meaning behind the piece. To view the art or submit your own piece, visit: https://patient.sm/B15-Artwork .
- Wear and “light up” orange: Show your support by wearing orange, the official World Patient Safety Day color, or lighting up your house, a local monument or business orange. Share your photos on social media between September 13th and September 17th. You can also purchase official campaign t-shirts and hats: https://patient.sm/B15-Shop .
This year’s event is made possible by the generous sponsorship of Dr. Steven J. Barker, Gordon & Betty Moore Foundation, HealthySimulation.com, Jewish Healthcare Foundation, Josie King Foundation, Kaiser Permanente, Liamar Healthcare, Medstar Health Institute for Quality and Safety and Teletracking. To learn more about #UniteForSafeCare, visit: https://patientsafetymovement.org/unite-for-safe-care/home/ .
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005375/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
